Yale Ventures’ Post

💹 Emerging Trends and Challenges in Neuroscience Development, sharing some takeaways. 1️⃣ Neuroscience Development Trends Investment in neuropsychiatric disorders is gaining momentum, with new drug approvals for conditions once considered untreatable. This shift is attracting venture capitalists and transforming the landscape. 2️⃣ Challenges in Neurodegenerative Disease Trials The unpredictability of regulatory approvals for diseases like Alzheimer's and Parkinson's was discussed. A holistic approach, focusing on both clearing and preventing aggregate formation, is seen as critical. 3️⃣ Execution Challenges in Clinical Trials Moving from Phase 2 to Phase 3 often introduces execution difficulties, particularly in maintaining team cohesion. Rigor in late-stage neuroscience trials is essential for success. 4️⃣ Need for Improved Measurement Tools Current clinical trial endpoints are outdated. The FDA recognizes this and is pushing for tools that better reflect patients' daily lives. Combining behavioral and translational endpoints could greatly improve our understanding of treatment outcomes. Wanted to share these key insights from the panel discussion at the 24th Biotech in Europe Forum held in Basel that highlights the future of this field. #Neuroscience #ClinicalTrials #Innovation #Healthcare #Learning

Excited to share that our latest study has been published! This work leverages computational analysis using the intrinsic ignition framework to investigate the dynamic brain network alterations in individuals with pharmacoresistant focal epilepsy. Our study examined resting-state fMRI scans from 10 patients and 30 healthy controls, focusing on functional network dynamics in both global and local brain regions. Key findings include: Increased global integration and metastability across the brain, reflecting substantial changes in connectivity. Distinctive network reorganization, with paradoxical dynamics in seizure onset zones and increased intrinsic ignition in distant brain areas, revealing pathways potentially critical for seizure propagation. These insights not only deepen our understanding of epilepsy mechanisms but also open new avenues for developing diagnostic biomarkers and targeted therapies. Proud to be a coauthor on this impactful research! #Epilepsy #Neuroimaging #ComputationalNeuroscience #N-brain

𝗠𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝟱𝟱 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗽𝗲𝗼𝗽𝗹𝗲 𝘄𝗼𝗿𝗹𝗱𝘄𝗶𝗱𝗲 𝗹𝗶𝘃𝗲 𝘄𝗶𝘁𝗵 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 𝗗𝗶𝘀𝗲𝗮𝘀𝗲—𝗮 𝗻𝗲𝘂𝗿𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗮𝗴𝗶𝗻𝗴 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿 𝗰𝗵𝗮𝗿𝗮𝗰𝘁𝗲𝗿𝗶𝘇𝗲𝗱 𝗯𝘆 𝗰𝗼𝗴𝗻𝗶𝘁𝗶𝘃𝗲 𝗰𝗵𝗮𝗻𝗴𝗲𝘀 𝘁𝗵𝗮𝘁 𝗶𝗻𝘁𝗲𝗿𝗳𝗲𝗿𝗲 𝘄𝗶𝘁𝗵 𝗱𝗮𝗶𝗹𝘆 𝗹𝗶𝗳𝗲. Saturday, September 21st was #WorldAlzheimersDay and an opportunity to raise awareness and challenge the stigma around Alzheimer’s as well as reflect on potential treatments and support for the families impacted by the disease. In our most recent Inscopix, Inc. blog, Melissa Martin writes about: - What is Alzheimer’s and how many individuals does it affect - What are typical difficulties in researching this disease and developing new therapeutics - Publications using miniscope technology to explore the basic biological science of the disease - Research groups using miniscope technology to explore potential treatments and translational tools for early detection Read the full blog here: https://lnkd.in/dha7brDM #neuroscience #dementia #alzheimers

If you have been following our Preskorn’s Perspective series, watch Sheldon Preskorn, MD's latest presentation, “From Chance Discovery to Molecular Biology.” In his talk, Dr. Preskorn explores the evolution of psychiatric drug development from early chance discoveries to modern, pathophysiology-based approaches. Learn how these advancements have led to more precise and effective treatment options over the last two decades. Watch the on-demand webinar now to gain insights into this significant shift in CNS drug discovery. https://hubs.li/Q02W6FNJ0 #cns #psychiatricdrug #drugdevelopment #drugdiscovery #webinar #neuroscience #drvinceclinicalresearch #DVCR

🌟 Thrilled to announce the publication of my latest review article in AIMS Neuroscience titled, "Novel Perspective of Therapeutic Modules to Overcome Motor and Nonmotor Symptoms in Parkinson’s Disease." In this article, we explore new and innovative therapeutic approaches to address both the motor and non-motor symptoms of Parkinson’s disease, focusing on personalized treatment strategies that not only alleviate symptoms but also aim to slow disease progression. 🧠 I would like to express my sincere gratitude to Dr. Ajay Kumar Gupta Sir for his invaluable guidance and suggestions, which greatly assisted me in the completion of this project. I would also like to acknowledge the contributions of Prashant Kumar Singh Sir, which were instrumental to the success of this endeavour. I am also thankful to my friends Ashish Verma, Aarohi Tiwari, and Satendra Chauhan. Their support helped me a lot. Excited to share our findings with the scientific community and contribute to the ongoing efforts to tackle neurodegenerative disorders. Check out the full article here: [https://lnkd.in/gikq2dg2] #ParkinsonsDisease #Neuroscience #Research #Therapeutics #Neurodegeneration #Innovation #Pharmacology

Vigil Neuroscience IGNITE trial update for iluzanebart in ALSP shows agility in the competitive neuroscience landscape. By adapting to FDA guidance and focusing on 12-month data, they're balancing regulatory compliance with potential accelerated approval. This move in the rare disease space could differentiate Vigil from competitors focused on more common neurodegenerative conditions. With results expected in early 2025, Vigil is setting clear expectations for stakeholders. Their strategy highlights the importance of regulatory flexibility and robust data in the fast-paced neuroscience biotech sector. Success here could attract more attention to rare neurodegenerative diseases, potentially shifting industry focus. #Neuroscience #BiotechInnovation #RareDiseases #ClinicalTrials

Exciting news! After significant effort led by Silvia Zaragoza Domingo, PhD we've finally published the paper on Methods for Neuroscience Drug Development: Guidance on Standardization of the Process for Defining Clinical Outcome Strategies in Clinical Trials. For those passionate about this topic, I highly recommend giving it a read! #Neuroscience #DrugDevelopment #ClinicalTrials

I am pleased to inform you that my peer-reviewed book chapter, "AI and XR-Powered Digital Therapeutics (DTx) Innovations," part of the Open Access book Navigating the Metaverse: A Comprehensive Guide to the Future of Digital Interaction, has been published today. You can access it for free here: https://lnkd.in/epnjuKM6 Cheers! Cited Companies: XR Therapeutics Penny Day; MedRhythms, Inc. Brian Harris Owen McCarthy; Unlearn.AI Marco Calderon #metaverse #artificialintelligence, #extendedreality, #digitaltherapeutics, #innovation, #technologyconvergence, #healthcare, #digitalhealth, #largelanguagemodels, #virtualreality, #augmentedreality, #mixedreality, #spatialcomputing, #commercialization, #productdesign, #diagnosis, #treatment, #disorders, #digitaltwins, #precisionmedicine, #clinicaltrials, #genomics, #mentalhealth, #neurology, #neuroscience, #oncology, #cognitivehealth, #ADHD, #Autism, #painmanagement

Sinaptica has developed a new form of personalized weekly brain stimulation for Alzheimer’s Disease (AD) that has been granted FDA breakthrough status based on unprecedented published sham-controlled Phase 2 data-- significantly slowing mild-to-moderate (M/M) AD on all functional and cognitive endpoints at 6 months, and on the primary and all key secondaries at 12 months in all three domains: cognition, function, and behavior, with virtually no side-effects.  Sinaptica’s technology is a new powerful form of rTMS with personalization (via concurrent pairing with EEG), precision (via Neuronavigation) and a proprietary ML algorithm and treats AD by enhancing neuroplasticity via neuromodulation of the Default mode network (DMN), a novel brain network responsible for episodic memory and strongly implicated in AD. Sinaptica is emerging as a leader in personalized precision brain stimulation with a connectomics-based platform that can address multiple brain disease states, starting with Alzheimer's and MCI. Meet Sinaptica Therapeutics, Inc. @ #Sachs_NIF More Info @ https://lnkd.in/dHgcp4fq #Neuroscience #Neurotech #NeurologyInnovation #BrainHealth #CNSDisorders #NeurologicalDiseases #ADPD #Neuropsychiatry #PsychedelicResearch #NeuroTechInvestment #Biotech #MedicalInnovation #NeuroscienceForum #NeuroInvestment #NextGenMedicine #NeuroscienceResearch #MentalHealthInnovation #BiotechIndustry

At @Mayo Clinic, 2024 brought transformative advancements in research. Dr. Kendall Lee and his team at Mayo Clinic are pioneering groundbreaking research into the neurobiology of addiction. By studying how deep brain stimulation can impact cravings and recovery, they’re opening doors to innovative treatments for those struggling with substance use disorders. This work highlights Mayo Clinic’s unwavering commitment to addressing complex medical challenges and improving patient lives. 📖 Learn more about this research and other transformative advancements in 2024: https://mayocl.in/3W1cXMG